GlassScriptPhysician profile
Govind B Patel
NPI 1073555249
$66,955.51
in general payments reported to CMS, 2019-2025
32 companies · $753 in 2025
The $753 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $26K · 2020: $24K · 2021: $13K · 2022: $670 · 2023: $1,095 · 2024: $669 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,495 · Education: $22.16.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,494.92 |
| Education | $22.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $36,820.81 | 2019-2025 | Entyvio, Eohilia |
| Shire North American Group INC | $26,078.00 | 2019 | |
| Abbvie INC. | $785.47 | 2020-2025 | |
| Janssen Biotech, INC. | $495.57 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Gilead Sciences, INC. | $482.33 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $371.70 | 2019-2025 | Ocaliva |
| Pfizer INC. | $284.89 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $210.77 | 2019-2024 | Xifaxan |
| Genzyme Corporation | $203.34 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $165.57 | 2024-2025 | Iqirvo, Bylvay |
| Ardelyx, INC. | $109.29 | 2024-2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $104.27 | 2023-2024 | Dupixent |
| Olympus America INC. | $98.46 | 2019-2022 | |
| Glaxosmithkline, LLC. | $93.81 | 2019-2021 | |
| Fresenius Kabi USA, LLC | $86.58 | 2023 | Idacio, Smoflipid |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $74.66 | 2019 | |
| Abbott Laboratories | $71.47 | 2021-2022 | |
| Lilly USA, LLC | $59.65 | 2020-2025 | Omvoh |
| Celgene Corporation | $59.32 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $54.80 | 2020 | |
| Sandoz INC. | $42.89 | 2023-2024 | Hyrimoz |
| Qol Medical, LLC | $32.00 | 2023 | Sucraid |
| Cordis US Corp. | $24.55 | 2022 | |
| Daiichi Sankyo INC. | $19.88 | 2024 | Injectafer |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.64 | 2023 | Cyltezo |
| Alfasigma USA, INC. | $18.34 | 2020 | |
| Organon LLC | $18.30 | 2022 | |
| Ethicon US, LLC | $16.92 | 2021 | |
| Merck Sharp & Dohme LLC | $16.49 | 2021 | |
| Medtronic, INC. | $13.19 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.06 | 2021 | |
| Capsovision, INC. | $9.49 | 2025 | Capsocam Plus |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Govind Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.